ERBB2 and breast cancer: In the phase 3 clinical trials MONARCH 2 and MONARCH 3, abemaciclib significantly improved outcomes in patients with HR + , HER2- advanced breast cancer in combination with an aromatase inhibitor as initial therapy [1] or with fulvestrant after progression on endocrine therapy [2, 3].